Display options
Cite
Hawkins-Taylor C, Carlson AM. Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil. Am Health Drug Benefits. 2013;6(7):401-12
Hawkins-Taylor, C., & Carlson, A. M. (2013). Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil. American health & drug benefits, 6(7), 401-12.
Hawkins-Taylor, Chamika, and Carlson, Angeline M. "Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil." American health & drug benefits vol. 6,7 (2013): 401-12.
Hawkins-Taylor C, Carlson AM. Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil. Am Health Drug Benefits. 2013 Sep;6(7):401-12. PMID: 24991371; PMCID: PMC4031729.
Copy Download .nbib Format: NLM
Share it on

Am Health Drug Benefits. 2013 Sep;6(7):401-12.

Communication Strategies Must Be Tailored to a Medication's Targeted Population: Lessons from the Case of BiDil.

American health & drug benefits

Chamika Hawkins-Taylor, Angeline M Carlson

Affiliations

  1. Health Improvement Coordinator with Blue Cross Blue Shield of Minnesota, Minneapolis.
  2. Clinical Assistant Professor, Department of Pharmaceutical Care & Health Systems, University of Minnesota College of Pharmacy, Minneapolis. This article is based on Dr Hawkins-Taylor's PhD dissertation at the University of Minnesota College of Pharmacy.

PMID: 24991371 PMCID: PMC4031729

Abstract

BACKGROUND: The American population's diversity continues to grow, and its racial and ethnic mixes are changing. The US healthcare system must confront this changing reality. The introduction of isosorbide dinitrate/hydralazine hydrochloride (BiDil) to the US marketplace was a move toward recognizing these changing consumer needs. BiDil was approved specifically as a secondary treatment for heart failure in African-American patients. It remains the first and only drug approved by the US Food and Drug Administration for a race-based indication. To ensure commercial success, a drug must be made "visible" to healthcare providers and to consumers.

OBJECTIVES: To describe and analyze the case of BiDil and its potential implications for drugs developed for targeted populations to help them avoid a similar fate of market withdrawal because of commercial considerations.

METHOD: This analysis is based on 12 comprehensive interviews with 5 clinical investigators, 1 minority healthcare provider, and 5 pharmaceutical representatives, as well as a review of the literature. Overall, 12 one-hour semistructured interviews were conducted. Of the 11 interviewees, 10 were interviewed once and 1 was interviewed once early in the process and then had a second interview by the end of the study. When the 12 scheduled interviews were completed, the recordings were transcribed and subjected to analysis through the use of a readily available computer software package, using concepts and themes collected from the literature and the interviewees' responses.

RESULTS: The interviewees lacked consensus regarding the unique nature of BiDil. The clinical researchers considered it innovative in identifying that taking the 2 drugs together produced the greatest clinical effect in African-American patients with heart failure. For them, BiDil represented an innovation in the emerging field of personalized medicine. However, they were dismayed to see that these beliefs were challenged by the medical community and their physician colleagues. They reported that practicing, mainly primary care physicians considered the development of a branded medication that combined 2 older drugs to be superfluous, because the same effect could be achieved by administering each agent individually at the same time. Obtaining a patent for BiDil, therefore, was seen simply as a desire for commercial gain. During the approval hearings, representatives of the sponsored company attributed these concerns to "misinformed physicians" and "uninformed patients."

CONCLUSION: The case of BiDil demonstrates that a marketing strategy for a population with unique health issues requires an understanding of underlying cultural, social, and economic underpinnings. Ignorance of these dynamics within the African-American community was blatantly reflected at the launch of the drug. Although BiDil remains a treatment option, there is no marketing effort to promote its use. The failure to capture the targeted market for the drug has important implications for the future of commercial considerations in the development of race-based medications.

References

  1. Ann Fam Med. 2006 Nov-Dec;4(6):556-60 - PubMed
  2. Heart Fail Clin. 2010 Jan;6(1):65-74 - PubMed
  3. Arch Intern Med. 2008 Jun 9;168(11):1152-8 - PubMed
  4. Am J Epidemiol. 2010 Sep 15;172(6):717-27 - PubMed
  5. Health Aff (Millwood). 2001 Sep-Oct;20(5):216-20 - PubMed
  6. Ann Intern Med. 2007 Jan 2;146(1):57-62 - PubMed
  7. Vital Health Stat 10. 2012 Jan;(252):1-207 - PubMed
  8. Hypertension. 2010 Feb;55(2):399-407 - PubMed
  9. Kennedy Inst Ethics J. 2012 Jun;22(2):83-90 - PubMed
  10. J Card Fail. 1999 Sep;5(3):178-87 - PubMed
  11. Am J Med Sci. 2003 Jun;325(6):315-31 - PubMed
  12. Ann Intern Med. 2007 Jan 2;146(1):52-6 - PubMed
  13. Br J Clin Pharmacol. 2001 Feb;51(2):184-9 - PubMed
  14. J Gen Intern Med. 1999 Sep;14(9):537-46 - PubMed
  15. Am Heart J. 2010 Oct;160(4):605-18 - PubMed
  16. Health Care Financ Rev. 2003 Winter;25(2):63-76 - PubMed
  17. N Engl J Med. 2004 Nov 11;351(20):2049-57 - PubMed
  18. Clin Ther. 2006 May;28(5):666-78 - PubMed
  19. Health Mark Q. 1995;12(4):93-111 - PubMed
  20. JAMA. 2013 Sep 4;310(9):918-29 - PubMed
  21. N Engl J Med. 1986 Jun 12;314(24):1547-52 - PubMed
  22. Health Aff (Millwood). 2006 Sep-Oct;25(5):1363-70 - PubMed
  23. Lancet. 2012 May 19;379(9829):1876; author reply 1876-7 - PubMed
  24. Prev Chronic Dis. 2012;9:E22 - PubMed
  25. Lancet. 2012 Jan 14;379(9811):114-5 - PubMed
  26. Am J Manag Care. 2003 Mar;9(3):225-34 - PubMed
  27. Am J Manag Care. 2005 Jan;11 Spec No:SP21-6 - PubMed

Publication Types